Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures. Existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension also participated in the round. This brings the company's funding to over €27 million.
The company is building an AI imaging laboratory to house Qureight’s 3D chest imaging Foundation Model, significantly reducing both the data requirement and the time needed to develop new disease models.
The Qureight platform includes:
Global imaging CRO services to improve image handling in clinical trials and support rapid site onboarding and patient inclusion decisions.
Proprietary AI Lung image biomarkers enable the quantification of compartment-specific structural changes that indicate disease progression in a clinical trial.
